Search form

Topics:

ubmslateCL-logo-ubm

CL Mobile Menu

Norman Bauman

Norman Bauman

Norman BaumanNorman Bauman

Norman Bauman is a freelance journalist based in New York who has been covering science and medicine for over 30 years. His publications include Biotechnology Newswatch, Medical World News, Medical Tribune, Oncology Times, Ophthalmology World News, and Urology Times.

Posts by Author

Plaque psoriasis. (Tanya Munger, MSN and Robert Bales, MD, MPH)

Guselkumab, a selective antagonist of IL-23, went head to head with adalimumab in a year-long phase 2 trial of 293 patients with moderate to severe plaque psoriasis. A quick synopsis of the results here.

Pyoderma gangrenosum. (David Effron, MD and Alex Green, DO)

A case report describes the use of anakinra in a patient with psoriatic arthritis in whom pyoderma gangrenosum developed. The ulcer had not responded to any other therapies.

Heliotrope rash in dermatomyositis

Hard, mobile, painless subcutaneous nodules developed in this woman who had had dermatomyositis for 20 years. The calcifications progressed during treatment with infliximab.

©thailoei92/shutterstock.com

This is the latest sortie in the war between over- and under-treatment of osteoporosis.

©Edward Cebria/shutterstock.com

This is a case report of a patient with rheumatoid arthritis in whom interstitial lung disease (ILD) developed. ILD is one of several pulmonary complications of RA.

©CLS Design/shutterstock.com

Here is the case of a 30-year-old man with scalp psoriasis in whom Koebner phenomenon developed at areas of developing shingles.

Hand deformities seen in Jaccoud's arthropathy are the result of soft-tissue abnormalities, not the destruction of bone joints seen in rheumatoid arthritis.

The cause underlying the 2009 phenomenon that left 1,300 persons with incurable narcolepsy has finally been elucidated.

New study results shed light on questions about the effect of combining drugs to treat osteoporosis and what happens after a switch from one drug to another.

The goal of 90% skin clearance is “reachable” for many patients with severe psoriasis with interleukin-17 (IL-17) inhibitors. A closer look here.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.